Raphe and ventrolateral medulla proteomics in epilepsy and sudden unexpected death in epilepsy

Dominique F. Leitner,1 Evgeny Kanshin,2 Manor Askenazi,3,4 Arline Faustin,5,6 Daniel Friedman,1 Sasha Devore,1 Beatrix Ueberheide,2,4,5 Thomas Wisniewski5,6,7 and Orrin Devinsky1

Brainstem nuclei dysfunction is implicated in sudden unexpected death in epilepsy. In animal models, deficient serotonergic activity is associated with seizure-induced respiratory arrest. In humans, glia are decreased in the ventrolateral medullary pre-Botzinger complex that modulate respiratory rhythm, as well as in the medial medullary raphe that modulate respiration and arousal. Finally, sudden unexpected death in epilepsy cases have decreased midbrain volume. To understand the potential role of brainstem nuclei in sudden unexpected death in epilepsy, we evaluated molecular signalling pathways using localized proteomics in microdissected midbrain dorsal raphe and medial medullary raphe serotonergic nuclei, as well as the ventrolateral medulla in brain tissue from epilepsy patients who died of sudden unexpected death in epilepsy and other causes in diverse epilepsy syndromes and non-epilepsy control cases (n = 15–16 cases per group/region). Compared with the dorsal raphe of non-epilepsy controls, we identified 89 proteins in non-sudden unexpected death in epilepsy and 219 proteins in sudden unexpected death in epilepsy that were differentially expressed. These proteins were associated with inhibition of EIF2 signalling (P-value of overlap = 1.29 × 10^{-8}, z = -2.00) in non-sudden unexpected death in epilepsy. In sudden unexpected death in epilepsy, there were 10 activated pathways (top pathway: gluconeogenesis I, P-value of overlap = 3.02 × 10^{-6}, z = 2.24) and 1 inhibited pathway (fatty acid beta-oxidation, P-value of overlap = 2.69 × 10^{-4}, z = -2.00). Comparing sudden unexpected death in epilepsy and non-sudden unexpected death in epilepsy, 10 proteins were differentially expressed, but there were no associated signalling pathways. In both medullary regions, few proteins showed significant differences in pairwise comparisons. We identified altered proteins in the raphe and ventrolateral medulla of epilepsy patients, including some differentially expressed in sudden unexpected death in epilepsy cases. Altered signalling pathways in the dorsal raphe of sudden unexpected death in epilepsy indicate a shift in cellular energy production and activation of G-protein signalling, inflammatory response, stress response and neuronal migration/outgrowth. Future studies should assess the brain proteome in relation to additional clinical variables (e.g. recent tonic–clonic seizures) and in more of the reciprocally connected cortical and subcortical regions to better understand the pathophysiology of epilepsy and sudden unexpected death in epilepsy.

1 Comprehensive Epilepsy Center, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA
2 Proteomics Laboratory, Division of Advanced Research Technologies, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA
3 Biomedical Hosting LLC, Arlington, MA 02140, USA
4 Department of Biochemistry and Molecular Pharmacology, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA
5 Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA
6 Department of Pathology, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA
7 Department of Psychiatry, Grossman School of Medicine, New York University, 223 East 34th Street, New York, NY 10016, USA

Received December 22, 2021. Revised April 29, 2022. Accepted July 11, 2022. Advance access publication July 12, 2022
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (doi:https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Sudden unexpected death in epilepsy (SUDEP) occurs in 1 in 1000 epilepsy patients every year, at higher rates in patients with treatment-resistant epilepsy. In epilepsy monitoring units, respiratory dysfunction often precedes SUDEP and likely results from brainstem dysfunction affecting autonomic and arousal systems. Prolonged postictal EEG suppression (PGES) after a generalized tonic–clonic seizure (GTCS) may impair arousal and respiration, causing a coma-like state with postictal central apnoea and hypoxia. Furthermore, the brainstem of SUDEP cases show medullary, pontine and midbrain atrophy. Compared with epilepsy patients who died from other causes and controls, SUDEP cases had decreased glia in medullary subregions. No molecular signature distinguishes SUDEP and other
Both medullary regions were available in 45 cases. There are a total of 68 cases for all regions (Supplementary Tables 1). Informed consent provided by next of kin. Cause of death was classified into non-SUDEP and SUDEP categories (definite SUDEP, definite SUDEP plus, probable SUDEP). Clinical history was determined from interviews and medical records. After neuropathological examination (T.W., A.F.) of NASR cases, brain tissue was processed into formalin-fixed paraffin-embedded blocks. Cases were selected with archival time in formalin <3 years, containing brainstem region of interest as confirmed anatomically and histologically for brainstem nuclei [tryptophan hydroxylase 2-positive (TPH2+) in both raphe nuclei; neurokinin receptor 1-positive (NK1R+) in VLM]. Cases were age- and sex-matched for available brain tissue fitting our criteria. Group sizes were determined by number of cases with significant findings as reported, including our epilepsy study with similar methods. Possible SUDEP, near SUDEP, and cases with insufficient information on cause of death were excluded. Our NASR cases were enrolled between May 2016 and June 2019 and included non-epilepsy controls (n = 4), non-SUDEP epilepsy (n = 16) and SUDEP (n = 25) cases. Non-epilepsy control (n = 15) and non-SUDEP epilepsy (n = 6) cases were obtained from the National Institutes of Health NeuroBioBank. Non-epilepsy control cases were also obtained from NYU Center for Biospecimen Research and Development (n = 2). Non-SUDEP categories of cause of death in the people with epilepsy (PWE) and control groups included cardiac arrest/disease, overdose/intoxication, trauma, drowning, pulmonary embolism, pneumonia, septic shock and suicide; see Supplementary Tables 1–3. PWE and SUDEP cases included diverse epilepsy syndromes. From a total of 68 cases, 137 regions for analysis with 15 cases/group in each brain region of interest were studied: 23 cases had all three brainstem nuclei regions available (23 cases only have DR) and 45 cases in medulla have both regions (one case has only MR). Case histories are summarized in Table 1 and detailed in Supplementary Tables 1–3 from cases with known information. Some NASR cases were not under regular medical care and had limited medical records. An overview schematic is provided in the Graphical Abstract, created with BioRender.com.

### Table 1 Case history summary

| Group            | Cases | Mean age at death (years) | Sex | Mean PMI (hours) | Mean brain weight (grams) |
|------------------|-------|---------------------------|-----|------------------|--------------------------|
| Midbrain DR      |       |                           |     |                  |                          |
| Control          | 15    | 37.1 ± 12.6               | 3 F/12 M | 18 ± 6           | 1468 ± 99               |
| PWE              | 16    | 43.1 ± 12.5               | 9 F/7 M | 29 ± 12          | 1352 ± 207              |
| SUDEP            | 15    | 31.7 ± 11.6               | 5 F/10 M | 41 ± 22          | 1382 ± 206              |
| Medulla MR       |       |                           |     |                  |                          |
| Control          | 15    | 39.3 ± 10.4               | 2 F/13 M | 23 ± 15          | 1457 ± 89               |
| PWE              | 16    | 36.9 ± 14.3               | 9 F/7 M | 38 ± 29          | 1347 ± 125              |
| SUDEP            | 15    | 28.3 ± 10.2               | 5 F/10 M | 35 ± 22          | 1419 ± 151              |
| Medulla VLM      |       |                           |     |                  |                          |
| Control          | 15    | 39.3 ± 10.4               | 2 F/13 M | 23 ± 15          | 1457 ± 89               |
| PWE              | 16    | 35.0 ± 12.4               | 9 F/6 M  | 35 ± 28          | 1349 ± 129              |
| SUDEP            | 15    | 28.3 ± 10.2               | 5 F/10 M | 35 ± 22          | 1419 ± 151              |

PMI = post-mortem interval.

PMI (n = 39 midbrain, n = 41 medulla) and brain weight (n = 40 midbrain, n = 43 medulla) are from cases with known information. There were 23 cases with all brain regions available. Both medullary regions were available in 45 cases. There are a total of 68 cases for all regions (Supplementary Tables 1–3).

### Materials and methods

#### Human brain tissue

Post-mortem brain tissue was collected with approval by the New York University (NYU) School of Medicine Institutional Review Board. Cases were obtained through the North American SUDEP Registry (NASR), National Institutes of Health NeuroBioBank and NYU Center for Biospecimen Research and Development. NASR began enrolling cases from NYU, multiple clinical and forensic collaborators in October 2011, with all cases having written informed consent provided by next of kin. Cause of death was classified into non-SUDEP and SUDEP categories (definite SUDEP, definite SUDEP plus, probable SUDEP). Clinical history was determined from interviews and medical records. After neuropathological examination (T.W., A.F.) of NASR cases, brain tissue was processed into formalin-fixed paraffin-embedded blocks. Cases were selected with archival time in formalin <3 years, containing brainstem region of interest as confirmed anatomically and histologically for brainstem nuclei [tryptophan hydroxylase 2-positive (TPH2+) in both raphe nuclei; neurokinin receptor 1-positive (NK1R+) in VLM]. Cases were age- and sex-matched for available brain tissue fitting our criteria. Group sizes were determined by number of cases with significant findings as reported, including our epilepsy study with similar methods. Possible SUDEP, near SUDEP, and cases with insufficient information on cause of death were excluded. Our NASR cases were enrolled between May 2016 and June 2019 and included non-epilepsy controls (n = 4), non-SUDEP epilepsy (n = 16) and SUDEP (n = 25) cases. Non-epilepsy control (n = 15) and non-SUDEP epilepsy (n = 6) cases were obtained from the National Institutes of Health NeuroBioBank. Non-epilepsy control cases were also obtained from NYU Center for Biospecimen Research and Development (n = 2). Non-SUDEP categories of cause of death in the people with epilepsy (PWE) and control groups included cardiac arrest/disease, overdose/intoxication, trauma, drowning, pulmonary embolism, pneumonia, septic shock and suicide; see Supplementary Tables 1–3. PWE and SUDEP cases included diverse epilepsy syndromes. From a total of 68 cases, 137 regions for analysis with 15 cases/group in each brain region of interest were studied: 23 cases had all three brainstem nuclei regions available (23 cases only have DR) and 45 cases in medulla have both regions (one case has only MR). Case histories are summarized in Table 1 and detailed in Supplementary Tables 1–3 from cases with known information. Some NASR cases were not under regular medical care and had limited medical records. An overview schematic is provided in the Graphical Abstract, created with BioRender.com.
**Brainstem nuclei identification**

For all cases, midbrain was obtained at the inferior colliculus level and included the cerebellar decussation (caudal to the red nuclei) and medulla was isolated at 1 cm above obex and blocked into four levels within this 1 cm when available.

To select nuclei of interest, all midbrain and medulla sections were subject to immunohistochemistry to confirm TPH2 in midbrain DR and medulla MR (containing both the raphe obscurus and raphe pallidus), as well as NK1R+/TPH2- in VLM on standard glass slides as described in the following context. The same histological markers were used to confirm nuclei localization on laser capture microdissection (LCM) slides as described. Representative photos were acquired with a SpotImaging camera using PathSuite 2.0 software (Fig. 1). NYU Center for Biospecimen Research and Development sectioned brain tissue for standard slides and NYU Experimental Pathology for LCM slides.

**Immunohistochemistry**

To identify whether brainstem sections contained relevant nuclei, specific markers were evaluated before LCM. Briefly, 8 µm sections were deparaffinized and rehydrated
through a series of xylenes and ethanol, followed by heat-induced antigen retrieval with 10 mM sodium citrate, 0.05% triton-x 100 at pH 6. After blocking in 10% normal donkey serum, sections were incubated overnight at 4°C with primary antibodies for TPH2 (1:250, Abcam ab121013) for midbrain or TPH2 and NK1R (1:100, Sigma S8305) for medulla. Secondary antibodies included donkey anti-goat Alexa-Fluor 488 (1:500, Thermo Fisher) and donkey anti-rabbit Alexa-Fluor 555 (1:500, Thermo Fisher), with nuclei counterstaining by Hoescht (1 mg/ml, Sigma B2261).

**Laser capture microdissection**

To localize brainstem nuclei, 8 µm brain tissue sections on LCM compatible PET (polyethylene terephthalate) membrane slides (Leica) were immunostained with TPH2 (1:250, Abcam ab121013) for midbrain or TPH2 and NK1R (1:100, Sigma S8305) for medulla. Immunohistochemistry was performed as previously described with air drying overnight in a loosely closed container.34 For the VLM, an overview scan for the entire section before LCM allowed for NK1R+ and anatomical localization. Using LCM, we microdissected 12 mm² of the VLM bilaterally and 4.5 mm² for the DR and MR into mass slides (Leica) were immunostained with TPH2 (1:250, Abcam ab121013) for midbrain or TPH2 and NK1R (1:100, Sigma S8305) for medulla. Label-free Quantitative (LFQ) MS Proteomics: LFQ MS assessed differential protein expression, as described previously.14,33

Protein extraction and digestion were done according to the SPEED workflow.35 Microdissected samples were incubated in 10 µl of trifluoroacetic acid for 10 min at 70°C with subsequent quenching in 90 µl of 2 M Tris containing 10 mM tris(2-carboxyethyl)phosphine and 40 mM 2-chloroacetamide. Samples were incubated at 95°C for 30 min, diluted with 500 µl of water containing 0.2 µg of sequencing grade trypsin (Promega). Digestions were performed overnight at 37°C and terminated by adding trifluoroacetic acid to final 2% (v/v). Peptides were loaded on C18 Evosep tips.

Pepitides were separated using Evosep One LC system on 15 cm × 150 µm ID column packed with 1.9 µm ReproSil-Pur C18 beads (Evosep, cat# EV1113) over 44 min acetonitrile gradient (predefined by 30SPD Evosep Method) and analyzed on QExactive HF-X instrument (Thermo Scientific) in data-independent acquisition (DIA) mode doing MS2 fragmentation across 22 m/z windows after every MS1 scan event. High-resolution full MS spectra were acquired with a resolution of 120,000, an AGC target of 3e6, with a maximum ion injection time of 60 ms and scan range of 350–1650 m/z. Following each full MS scan, 22 data-independent HCD MS/MS scans were acquired at the resolution of 30,000, AGC target of 3e6, stepped NCE of 22.5, 25 and 27.5.

**Proteomics computational analysis**

DIA MS data were analyzed in Spectronaut (https://biognosys.com/shop/spectronaut)14,33 and searched in directDIA mode against the SwissProt subset of the human Uniprot database (http://www.uniprot.org/). Database search was performed in integrated search engine Pulsar. For searching, the enzyme specificity was set to trypsin with the maximum number of missed cleavages set to 2. Oxidation of methionine was searched as variable modification; carbamidomethylation of cysteines was searched as a fixed modification. The false discovery rate (FDR) for peptide, protein and site identification was set to 1%. Protein quantification was performed on MS2 level using three most intense fragment ions per precursor. Data set was compared against 248 common laboratory contaminants14,33 and 28 proteins were removed. LFQ normalization was performed for each brain region separately.36 Subsequent data analysis and visualization were performed in the R environment for statistical computing and graphics (http://www.r-project.org/).

**Statistical analyses**

The protein expression matrix (n = 2268) was filtered to contain only proteins that were quantified in ≥ 8 cases in at least one condition (control, PWE or SUDEP) in any brain region (n = 2237). For principal component analysis (PCA), missing values were imputed from the normal distribution with a width of 0.3 and downshift of 1.8 (relative to measured protein intensity distribution) in Perseus.37 A one-way ANOVA with q value correction followed by a Tukey’s post hoc test was performed to detect significant changes in protein expression among the control, PWE and SUDEP cases in the R environment (http://www.r-project.org/). Thresholds set for significance were an ANOVA q value < 0.05 calculated using the FDR method and a Tukey’s post hoc P-value < 0.05. A comparison of the proteins detected common to each region, as well as the significant proteins, were evaluated by Venn diagram generated from InteractiVenn.38 Cell-type-specific annotations were included in Supplementary Tables 4–6 and on volcano plots, from a reference data set39 and as described previously.14,33 Annotations were included when a protein had only one associated cell type and when the annotation included more than one associated cell type but were only neuronal proteins, for a total of 1066 possible annotations. Correlation analyses were performed by Pearson correlation in GraphPad Prism.

**Pathway analysis**

The signalling pathways associated with the differentially expressed proteins in each region were assessed by Ingenuity Pathway Analysis (Qiagen). A core analysis was performed for each brain region with a threshold for each protein with ANOVA q value < 0.05 and Tukey’s post hoc P-value.
<0.05. Coronavirus Pathogenesis Pathway is included in the supplemental table output but not included in the total number of significantly associated pathways as this study was performed before the COVID-19 pandemic.

Data availability
All data needed to evaluate our conclusions are present in the article and Supplementary data. Additional data related to this article may be requested from the authors. MS RAW files were uploaded on MassIVE repository (https://massive.ucsd.edu/) with the following dataset ID MSV000088563.

Results
Brainstem nuclei identification
We confirmed midbrain DR by serotonergic-positive (TPH2+) neurons (Fig. 1A). The MR were identified by TPH2+ neurons, located medially 6–10 mm above obex (Fig. 1C). Localization of the VLM was confirmed by NK1R+ cells and TPH2- neurons laterally 6–10 mm above obex (Fig. 1E). The same histological markers were then used on LCM sections to guide microdissection in addition to anatomical landmarks.

Proteomics differential expression analysis
From the three microdissected regions, 2268 proteins were detected in ≥ 8 cases/group of a region with 2237 detected in all three regions (Fig. 2A). A PCA in each brain region indicated a significant separation in PCA1 of the DR between SUDEP and control cases (one-way ANOVA Tukey post hoc test, P = 0.0083, Fig. 2B). There was more variability in PCA1 for control and PWE cases in each brain region (Fig. 2B–D).

Differential expression analysis using a one-way ANOVA with q value correction followed by a Tukey’s post hoc test, the largest protein changes were in the DR of SUDEP compared with control cases (219 proteins) followed by PWE compared with control cases (89 proteins; Fig. 3, Supplementary Table 4). Of changes in SUDEP cases, 131/219 proteins were uniquely significant to SUDEP and 10/
219 proteins significantly differed between SUDEP and PWE (Fig. 3A). The top significant proteins identified in DR are summarized in Tables 2 and 3 and detailed in Supplementary Tables 4 and 7. Fewer protein differences were identified in the two medullary nuclei among all group comparisons (Fig. 3, Supplementary Tables 5, 6 and 8).
Most significant proteins have an ‘undefined’ cell type annotation, ubiquitously expressed in multiple cell types or the cell type association is unknown (Fig. 3, Supplementary Tables 4–6). For annotated proteins, most are neuronal or are specifically excitatory or inhibitory neuron. One significant protein was associated with a glial annotation; transferrin (Tf; P02787) was increased in the VLM of SUDEP cases compared to control (1.80-fold) and PWE (1.56-fold) cases.

To determine the signalling pathways associated with protein changes, pathway analysis in the DR of PWE compared to control cases (89 proteins) indicated that these proteins were associated with 36 signalling pathways (P-value of overlap < 0.05) and one pathway was significantly impacted by fold change (|z| > 2, Supplementary Table 9). There was significant inhibition of EIF2 signalling (P-value of overlap = 1.28 × 10⁻⁸, z = –2.00, Fig. 4A). Comparing SUDEP and

### Table 2 Top 20 differentially expressed proteins in dorsal raphe of SUDEP versus control

| Gene     | Protein                                  | UniProt ID | ANOVA P-value | ANOVA q value | Tukey P-value | Fold change |
|----------|------------------------------------------|------------|---------------|---------------|---------------|-------------|
| Decreased | DDX17 Probable ATP-dependent RNA helicase DDX17 | Q92841     | 2.18E-05      | 8.82E-03      | 1.29E-05      | 1.32        |
|          | RPS3 40S ribosomal protein S3             | P23396     | 2.60E-05      | 8.82E-03      | 1.76E-05      | 1.30        |
|          | DDX3X ATP-dependent RNA helicase DDX3X    | O00571     | 4.24E-05      | 9.58E-03      | 3.54E-05      | 1.29        |
|          | PLPP3 Phospholipid phosphatase 3          | O14495     | 9.78E-05      | 1.54E-02      | 6.04E-05      | 1.51        |
|          | HSDL17B4 Peroxisomal multifunctional enzyme type 2 | P15659     | 1.02E-04      | 1.54E-02      | 7.91E-05      | 1.40        |
|          | FLII Protein flightless-1 homologue       | Q13045     | 6.13E-05      | 1.19E-02      | 8.93E-05      | 1.26        |
|          | ANXA6 Annexin A6                         | P08133     | 3.96E-05      | 9.58E-03      | 1.08E-04      | 1.30        |
|          | EEF2 Elongation factor 2                 | P13639     | 2.27E-04      | 2.20E-02      | 1.46E-04      | 1.20        |
|          | EIF4A1 Eukaryotic initiation factor 4A-I  | P60842     | 1.86E-04      | 2.10E-02      | 1.83E-04      | 1.28        |
|          | ACAD9 Complex I assembly factor ACAD9, mitochondrial | Q98485     | 4.07E-04      | 2.41E-02      | 2.58E-04      | 1.32        |
|          | PFKM ATP-dependent 6-phosphofructokinase, muscle type | P08237     | 3.82E-04      | 2.41E-02      | 2.83E-04      | 1.20        |

### Table 3 Top 20 differentially expressed proteins in dorsal raphe of PWE versus control

| Gene     | Protein                                  | UniProt ID | ANOVA P-value | ANOVA q value | Tukey P-value | Fold change |
|----------|------------------------------------------|------------|---------------|---------------|---------------|-------------|
| Increased | PSMB4 Proteasome subunit beta-type-4     | P28070     | 2.01E-05      | 8.82E-03      | 2.86E-04      | 2.05        |
|          | CRNP1 CB1 cannabinoid receptor-interacting protein I | Q96F85     | 2.37E-05      | 8.82E-03      | 3.30E-05      | 1.40        |
|          | PRPH Peripherin                          | P41219     | 4.04E-04      | 2.41E-02      | 1.64E-03      | 1.45        |
|          | PAX5 NAD(P)H-hydrate epimerase           | Q8NCW5     | 4.16E-04      | 2.41E-02      | 2.60E-03      | 2.17        |
|          | PTGR2 Prostaglandin reductase 2          | Q8N8N7     | 2.66E-03      | 3.61E-02      | 3.02E-03      | 1.81        |
|          | GSS Glutathione synthetase               | P48637     | 2.88E-03      | 3.63E-02      | 3.11E-03      | 1.72        |
|          | RCN1 Reticulocalbin-1                    | Q15293     | 1.63E-03      | 3.12E-02      | 3.22E-03      | 1.36        |
|          | CAST Calpastatin                         | P20810     | 2.30E-03      | 3.39E-02      | 3.32E-03      | 2.44        |
|          | CAPN5 Calpain-5                         | O15484     | 3.42E-03      | 3.63E-02      | 4.10E-03      | 5.12        |
|          | SBNS Suprabasin                          | Q6JWVP8    | 6.22E-03      | 4.34E-02      | 4.58E-03      | 2.56        |

| Decreased | ANXA6 Annexin A6                         | P08133     | 3.96E-05      | 9.58E-03      | 3.68E-04      | 1.27        |
|          | KIF21A Kinesin-like protein KIF21A       | Q7Z456     | 5.60E-04      | 2.62E-02      | 8.60E-04      | 1.15        |
|          | FLII Protein flightless-1 homologue      | Q13045     | 6.13E-05      | 1.19E-02      | 1.25E-03      | 1.21        |
|          | MX1 Interferon-induced GTP-binding protein Mxi | P20591     | 2.17E-04      | 2.10E-02      | 1.33E-03      | 1.55        |
|          | ARPC2 Actin-related protein 2/3 complex subunit 2 | O15144     | 6.92E-04      | 2.64E-02      | 1.38E-03      | 1.15        |
|          | DDX3X ATP-dependent RNA helicase DDX3X    | O00571     | 4.24E-05      | 9.58E-03      | 3.44E-03      | 1.19        |
|          | LYPLA2 Acyl-protein thioesterase 2       | O95372     | 3.31E-03      | 3.63E-02      | 4.06E-03      | 1.22        |
|          | TACO1 Translational activator of cytochrome c oxidase 1 | Q9859H4    | 3.58E-03      | 3.65E-02      | 4.32E-03      | 1.40        |
|          | RPS3 40S ribosomal protein S3             | P23396     | 2.60E-05      | 8.82E-03      | 5.29E-03      | 1.18        |
|          | EIF4A1 Eukaryotic initiation factor 4A-I  | P60842     | 1.86E-04      | 2.10E-02      | 5.59E-03      | 1.20        |
There were 10 activated and 1 inhibited signalling pathways (Fig. 4B). The most significantly activated pathway was gluconeogenesis I (P-value of overlap = 3.00 × 10^{-6}, z = -2.00). EIF2 signalling was the most enriched pathway in PWE and SUDEP regardless of z score, reaching a significant z score in PWE while in SUDEP there were additional proteins differentially expressed resulting in a lower absolute z score for this pathway (P-value of overlap = 3.51 × 10^{-13}, z = -1.67). Among 9 of the 11 significant signalling pathways in SUDEP versus control, there were shared proteins across these different signalling pathways related to G-protein signalling (e.g. increased CACNA2D1, CACNA2D2, GNB2 and GNAS in G beta gamma, GNRH, opioid signalling). Among 4 of the 11 pathways, unique proteins were not shared with other signalling pathways: inflammatory response (CCR3 signalling in eosinophils, MAPK signalling in promoting pathogenesis of influenza), stress response (including PRDX6 in xenobiotic metabolism general signalling pathway, endothelin-1 signalling) and neuronal migration/outgrowth (CDK5 signalling). Comparing SUDEP and PWE in the DR, 19 pathways were associated with 10 altered proteins but none had a significant z score (|z| > 2).

In the medulla, few significant proteins were identified in the MR in all group comparisons; thus, no associated signalling pathways. In the VLM, there were fewer significant proteins identified with 60 pathways associated with the 9 proteins in PWE versus control, 37 pathways associated with the 15 proteins in SUDEP versus control and 7 pathways associated with the 10 proteins in SUDEP versus PWE (Supplementary Tables 12–14). None of the VLM pathways had a significant z score (|z| > 2).

Although no significant pathways overlapped between PWE and SUDEP when compared to control cases in the DR, the 219 significant proteins altered in SUDEP versus control cases were highly correlated to the fold changes seen in PWE versus control cases (P < 0.0001, R² = 0.87, Fig. 4C). This indicates that many protein changes in SUDEP also trend in PWE versus control cases but do not reach significance.

Regional overlap of significantly different proteins indicated no shared protein changes when comparing PWE versus control cases, three proteins when comparing SUDEP versus control cases and one protein when comparing SUDEP versus PWE cases (Fig. 5A–C). IGH2 (Immunoglobulin Heavy Constant Gamma 2, P01859) was increased in the DR and VLM of SUDEP versus both PWE and control cases. In addition, in the DR and VLM, HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C, P07910) was decreased in SUDEP when compared with control. In the MR and VLM, SLC25A25 (Solute Carrier Family 25 Member 25, Q6KCM7) was increased in SUDEP when compared to control cases. With few significant proteins having regional overlap, no signalling pathways were enriched. Correlation analyses indicated that of all significant protein changes in a region, there is a significant correlation with other brainstem regions analyzed except when comparing DR and VLM for SUDEP versus PWE due to a large difference in one protein (leucine rich repeat containing 15, LRRC15, Q8TF66, acid beta-oxidation I (P-value of overlap = 3.00 × 10^{-6}, z = -2.00). EIF2 signalling was the most enriched pathway in PWE and SUDEP regardless of z score, reaching a significant z score in PWE while in SUDEP there were additional proteins differentially expressed resulting in a lower absolute z score for this pathway (P-value of overlap = 3.51 × 10^{-13}, z = -1.67). Among 9 of the 11 significant signalling pathways in SUDEP versus control, there were shared proteins across these different signalling pathways related to G-protein signalling (e.g. increased CACNA2D1, CACNA2D2, GNB2 and GNAS in G beta gamma, GNRH, opioid signalling). Among 4 of the 11 pathways, unique proteins were not shared with other signalling pathways: inflammatory response (CCR3 signalling in eosinophils, MAPK signalling in promoting pathogenesis of influenza), stress response (including PRDX6 in xenobiotic metabolism general signalling pathway, endothelin-1 signalling) and neuronal migration/outgrowth (CDK5 signalling). Comparing SUDEP and PWE in the DR, 19 pathways were associated with 10 altered proteins but none had a significant z score (|z| > 2).

In the medulla, few significant proteins were identified in the MR in all group comparisons; thus, no associated signalling pathways. In the VLM, there were fewer significant proteins identified with 60 pathways associated with the 9 proteins in PWE versus control, 37 pathways associated with the 15 proteins in SUDEP versus control and 7 pathways associated with the 10 proteins in SUDEP versus PWE (Supplementary Tables 12–14). None of the VLM pathways had a significant z score (|z| > 2).

Although no significant pathways overlapped between PWE and SUDEP when compared to control cases in the DR, the 219 significant proteins altered in SUDEP versus control cases were highly correlated to the fold changes seen in PWE versus control cases (P < 0.0001, R² = 0.87, Fig. 4C). This indicates that many protein changes in SUDEP also trend in PWE versus control cases but do not reach significance.

Regional overlap of significantly different proteins indicated no shared protein changes when comparing PWE versus control cases, three proteins when comparing SUDEP versus control cases and one protein when comparing SUDEP versus PWE cases (Fig. 5A–C). IGH2 (Immunoglobulin Heavy Constant Gamma 2, P01859) was increased in the DR and VLM of SUDEP versus both PWE and control cases. In addition, in the DR and VLM, HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C, P07910) was decreased in SUDEP when compared with control. In the MR and VLM, SLC25A25 (Solute Carrier Family 25 Member 25, Q6KCM7) was increased in SUDEP when compared to control cases. With few significant proteins having regional overlap, no signalling pathways were enriched. Correlation analyses indicated that of all significant protein changes in a region, there is a significant correlation with other brainstem regions analyzed except when comparing DR and VLM for SUDEP versus PWE due to a large difference in one protein (leucine rich repeat containing 15, LRRC15, Q8TF66,
Figure 5 Brainstem regional overlap of differentially expressed proteins. Regional overlap of differentially expressed proteins after a one-way ANOVA with q value correction followed by a Tukey’s post hoc test. (A) When comparing PWE and control, there are no commonly significant proteins among the three regions analyzed. (B) When comparing SUDEP and PWE, there is one protein (IGHG2) that is increased in SUDEP in both the DR and VLM. (C) When comparing SUDEP and control, there are two proteins (IGHG2 increased, HNRNPC decreased) that are altered in both the DR and VLM. SLC25A25 is also increased in SUDEP in both the MR and VLM. (D–L) Correlation analyses between the various brainstem regions of all significant proteins, with included nuclei indicated on the left. (D, G and J) Correlation analyses indicated that the 100 significant proteins across all brainstem regions in PWE versus control were significant when comparing DR versus MR, DR versus VLM and MR versus VLM. (E, H and K) Correlation analyses indicated that the 20 significant proteins across all brainstem regions in SUDEP versus PWE were significant when comparing DR versus MR and MR versus VLM. There was no correlation in DR versus VLM, due to the difference in expression for LRRC15. This protein is detected in fewer cases in both of these regions, and it is not detected in the MR. (F, I and L) Correlation analyses indicated that the 234 significant proteins across all brainstem regions in SUDEP versus control were significant when comparing DR versus MR, DR versus VLM and MR versus VLM. In purple are the proteins with a fold change in the same direction and in yellow are proteins with a fold change in the opposite direction.
Fig. 5D–L). In the VLM, LRRC15 had a 93.58-fold change when comparing SUDEP and PWE (Supplementary Tables 6 and 8), which was largely due to the low detection of this protein in most cases indicated by both a lower LFQ value and with at least eight cases having detected protein in the PWE group but not in the control or SUDEP groups.

**Comparison to hippocampus and cortex**

A comparison of the detected proteins in this data set to our previous non-SUDEP epilepsy data set in hippocampus and cortex\(^3\) (three overlapping cases) indicates 1976 common proteins to all brain regions, with 292 proteins unique to brainstem and 1240 proteins unique to the cortex and hippocampus (Supplementary Fig. 1A). The top signalling pathway associated with the unique brainstem proteins was coagulation system (P-value of overlap = 7.94 × 10\(^{-12}\)) and in the hippocampus/cortex was synaptogenesis signalling pathway (P-value of overlap = 1.0 × 10\(^{-25}\)). Of the shared proteins, the top enriched pathway was EIF2 signalling (P-value of overlap = 2.28 × 10\(^{-34}\)). Of the significant proteins identified in the DR when comparing PWE versus control (n = 89 proteins), 81 were detected in cortex or hippocampus. There was a negative correlation of the fold change in proteins with the dentate gyrus (P = 0.0003, R\(^2\) = 0.17) and no correlation with the frontal cortex (P = 0.77, R\(^2\) = 0.0011) or hippocampus (P = 0.85, R\(^2\) = 0.00049; Supplementary Fig. 1B–D). EIF2 signalling was activated in the hippocampus (58 proteins) and frontal cortex (28 proteins), rather than inhibited as it was in the DR (10 proteins). There was a difference in the P-value of overlap; more significant in the hippocampus and cortex than the DR. Only two significant proteins were in the MR of PWE versus control (too few for a correlation analysis), which were detected in the cortex or hippocampal regions. In the VLM, seven of the nine significant proteins were detected in the cortex and hippocampal regions. There was a positive correlation in all regions: hippocampus (P = 0.0063, R\(^2\) = 0.53), frontal cortex (P = 0.0069, R\(^2\) = 0.80) and in dentate gyrus (P = 0.0003, R\(^2\) = 0.94; Supplementary Fig. 1E–G). This indicates that significant protein changes in the hippocampus and cortex trend in the same direction of other brain regions when comparing PWE and SUDEP.

**Discussion**

Our study identified altered proteins in the human raphe and VLM of the brainstem in diverse epilepsy syndromes that were more prominent in SUDEP cases, particularly in the midbrain DR. Top signalling pathways associated with these proteins indicated a shift in energy production (increased gluconeogenesis, decreased fatty acid beta-oxidation), and activated pathways associated with G-protein signalling, inflammatory response, stress response, and neuronal migration/ouergrowth. DR changes in SUDEP also trended in PWE, supporting a potential progressive pathological process. A comparative analysis among brainstem regions and other previously evaluated cortical regions indicated similar global and region-specific protein changes in PWE and SUDEP.

**Midbrain**

We identified changes in cellular energy production pathways in the midbrain DR of SUDEP, which may result from multiple pathogenic mechanisms or factors. Glucose metabolism may be impaired in epilepsy, which disrupts energy homeostasis that maintains neuronal membrane potentials and can foster seizure generation in a feed-forward cycle, demanding more energy to re-establish homeostasis and perform cellular repair.\(^3\) Impaired glucose metabolism may result from reduced glucose transport, decreased pyruvate dehydrogenase in oxidative metabolism and increased energy demands.\(^5\) PET imaging identified hypometabolism, reflecting low glucose transport and utilization, in epilepsy patients\(^4\) and in the frontal lobe of high-risk SUDEP patients.\(^5\) Uncontrolled seizures from anti-seizure medication (ASM) non-adherence, medication changes or withdrawal, and treatment-resistant epilepsy may disrupt homeostasis and increase energy needs. Many ASMs reduce neurotransmission, lowering brain energy requirements.\(^5\) Astrocytes regulate glycolysis and gluconeogenesis,\(^5\) providing an alternative glucose source via gluconeogenesis in ischaemic stroke and brain tumours (where lactate accumulates and
In addition to altered gluconeogenesis in SUDEP, we found decreased fatty acid beta-oxidation, which normally occurs in astrocytes. The brain prefers glycolysis over fatty acid beta-oxidation, which requires less oxygen, minimizes superoxide production and oxidative stress response, and more rapidly generates ATP. Impaired astrocyte energy production in midbrain DR of SUDEP may reflect altered neuronal energy production or demands, astrocyte dysfunction, or a protective response to minimize oxidative damage in epilepsy.

The midbrain DR of SUDEP revealed activated pathways related to G-protein signalling (G beta gamma, GNRH, opioid signalling), inflammatory response (CCR3, MAPK signalling in promoting pathogenesis of influenza), stress response (xenobiotic metabolism general signalling pathway, endothelin-1 signalling), and neuronal migration/outgrowth (CDK5 signalling). We found a significant positive correlation of SUDEP proteins and PWE proteins in the midbrain DR (e.g. decreased EIF2 signalling), suggesting a pro-

progressive pathogenic process in neurons that mediate the arousal response to hypercapnia. MRI studies found brainstem atrophy from the medulla into the midbrain in SUDEP cases, activation of DR serotonergic neurons in an animal epilepsy model suppressed tonic seizures and respiratory arrest, and DR activation reduced PGES length. We did not detect changes related to serotonin signalling (TPH2 and SERT were not different, serotonin receptors were not detected). The midbrain of epilepsy patients is structurally normal.

No proteomic or histological studies beyond neuropathology examined the midbrain in epilepsy patients. Our results and previous studies indicate that the role of the midbrain DR in SUDEP deserves further investigation, particularly on mechanism, astrocytes versus neurons, disease progression, ASMs and other factors.

Medulla

In the medulla, we observed fewer protein changes in SUDEP and PWE. Previous studies of histological markers in medullary subregions identified differences between PWE or SUDEP to non-epilepsy controls (MBP, SYP, MAP2, GAL, SST, NK1R, TPH2, SERT). Vimentin+ and connexin 43+ astrocyte populations were decreased in SUDEP cases compared with PWE. In medullary subregions, no changes in markers of inflammation or blood–brain barrier (BBB) disruption (CD163, HLA-DR, IgG and albumin) were found in SUDEP cases. Few other medullary differences were identified in SUDEP versus PWE. Here, we observed one significant protein with a glial, oligodendrocyte, annotation (Tf). Tf was increased in the VLM of SUDEP compared with PWE and control cases (MBP, vimentin, connexin-43 were similar). In the brain, Tf is synthesized by oligodendrocytes and choroidplexus, and the protein is taken up by other cell types but may be present in capillary serum. Increased Tf in the highly myelinated VLM region may reflect processes related to myelin damage, increased cellular uptake of Tf, or BBB disruption. In epilepsy patients, decreased MBP occurs in medullary subregions, hippocampus and frontal cortex, as well as in the hippocampus of an epilepsy animal model. Increased Tf can occur after traumatic brain injury (TBI) or haemorrhage with BBB disruption. BBB disruption can occur in epilepsy, with IgG leakage, increased perivascular albumin and decreased ZO-1 in epilepsy patients and animal models. In our study, BBB permeability in the VLM was suggested by increased IGHG2 and HPX and decreased TJP1 (also known as ZO-1) in SUDEP compared with PWE and non-epilepsy controls. In addition, IGHG2 and HBG1 were increased in the DR of SUDEP compared with PWE. Changes to BBB permeability or vasculature changes in brainstem deserve further study, including whether these changes might be reflected in plasma or CSF as in TBI and aging.

Future studies in the medulla may also be of interest to identify cell type- and nuclei- (i.e. raphe obscurus, raphe pallidus, arcuate nucleus) specific differences in SUDEP.

Regional comparisons

A comparison of proteins across different brain regions indicates similar global and brain region-specific changes in PWE and SUDEP, with altered proteins in the DR being more unique. With few significant proteins identified in the medulla, there was little overlap of significant proteins among the brainstem regions analyzed. To determine whether there was a trend in similar proteins, an evaluation of significant proteins identified in at least one brainstem region of a pairwise comparison indicated a correlation across all brainstem regions (with the exception of one protein with low detection—LRRC15). Compared with our data in other cortical regions, there were fewer similarities but identified significant correlations of proteins in at least one brainstem region and cortical regions. Compared with PWE and controls, the significant VLM proteins trended in the same direction as other brain regions but not in DR (reflected by differences in activation/inhibition of the EIF2 signalling pathway). Comparing SUDEP and PWE, the significant brainstem protein changes trended in the same direction as other brain regions, except the dentate gyrus. We expected similar global- and region-specific protein changes, as in other studies.

With reciprocally connected brain regions, it may be of interest in future studies to evaluate how disease duration influences these protein changes particularly with progressive midbrain atrophy observed in SUDEP by MRI and a negative correlation of brain weight and epilepsy duration in SUDEP.

Limitations

Our study had several limitations. Although we were able to detect regional differences in microdissected tissue, fewer large membrane proteins are detected by this technique. There was limited availability of brainstem tissue with specific regions of interest from all cases, thus not all cases had all three brain regions. Case referral to NASR was skewed by sources from the San Diego Medical Examiner Office (mainly low socio-economic white and Hispanic
patients) and direct referrals (mainly high socio-economic white patients). We evaluated the broad changes evident from a heterogeneous group of cases with various epilepsy syndromes, seizure types and other clinical history. The availability of this critical brain region from well characterized cases is reinforced so that future studies can evaluate how the identified protein changes relate to specific clinical variables, i.e. epilepsy syndrome, seizure types, GTCS frequency and pathogenic gene variants.

Conclusions

In summary, our study identified differential expression of proteins in the human epileptic raphe and VLM that were more pronounced in SUDEP, particularly in the midbrain DR. Top signalling pathways associated with these proteins indicated a shift in energy production, and increased G-protein signalling, inflammatory response, stress response, and neuronal migration/outgrowth. Future studies should evaluate how additional clinical variables from well characterized cases influence these protein changes (i.e. number of recent GTCS, ASMs), follow up mechanistic studies related to the proteomic signature identified in the DR, investigate specific epilepsy syndromes, and evaluate additional brainstem nuclei to understand and reduce SUDEP risk.

Acknowledgements

The authors thank the participating families and clinicians for their involvement with the NASR.

Funding

National Institute of Neurological Disorders and Stroke U01 NS090415 05 Center for SUDEP Research: The Neuropathology of SUDEP, Finding A Cure for Epilepsy and Seizures (FACES), and National Institute on Aging P30AG066512. The proteomics work was in part supported by the New York University School of Medicine and P01AG060882.

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at Brain Communications online.

References

1. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: Epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075–1088. doi:10.1016/S1474-4422(16)30155-8.
2. Ryvlin P, Nashef L, Lhatoo SD, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): A retrospective study. Lancet Neurol. 2013;12(10):966–977. doi:10.1016/S1474-4422(13)70214-X.
3. Villella L, Lacuey N, Hampson JP, et al. Incidence, recurrence, and risk factors for peri-ictal central apnea and sudden unexpected death in epilepsy. Front Neurol. 2019;10:166. doi:10.3389/fneneurol.2019.00166.
4. Villella L, Lacuey N, Hampson JP, et al. Postconvulsive central apnea as a biomarker for sudden unexpected death in epilepsy (SUDEP). Neurology. 2019;92(3):e171–e182. doi:10.1212/WNL.0000000000006785.
5. Lacuey N, Zonjy B, Hampson JP, et al. The incidence and significance of perisial apnea in epileptic seizures. Epilepsia. 2018;59(3):573–582. doi:10.1111/epi.14006.
6. Lacuey N, Martins R, Villella L, et al. The association of serotonin reuptake inhibitors and benzodiazepines with ictal central apnea. Epilepsy Behav. 2019;98(Pt A):73–79. doi:10.1016/j.yebeh.2019.06.029.
7. Rheims S, Alvarez BM, Alexandre V, et al. Hypoxemia following general convulsive seizures: Risk factors and effect of oxygen therapy. Neurology. 2019;92(3):e183–e193. doi:10.1212/WNL.0000000000007777.
8. Mueller SG, Nei M, Bateman LM, et al. Brainstem network disruption: A pathway to sudden unexplained death in epilepsy? Hum Brain Mapp. 2018;39(12):4820–4830. doi:10.1002/hbm.24325.
9. Patodia S, Paradiso B, Ellis M, et al. Characterisation of medullary astrocytic populations in respiratory nuclei and alterations in sudden unexpected death in epilepsy. Epilepsia Res. 2019;157:106213. doi:10.1016/j.epilepsres.2019.106213.
10. Michalak Z, Obari D, Ellis M, Thom M, Sisodiya SM. Neuropathology of SUDEP: Role of inflammation, blood-brain barrier impairment, and hypoxia. Neurology. 2017;88(6):551–561. doi:10.1212/WNL.0000000000005384.
11. Patodia S, Somani A, O’Hare M, et al. The ventrolateral medulla and medullary raphe in sudden unexpected death in epilepsy. Brain. 2018;141(6):1719–1733. doi:10.1093/brain/awy078.
12. Patodia S, Tan I, Ellis M, et al. Medullary tyrosine hydroxylase catecholaminergic neuronal populations in sudden unexpected death in epilepsy. Brain Pathol. 2021;31:133–143. doi:10.1111/bpa.12891.
13. Patodia S, Tachrount M, Somani A, et al. MRI and pathology correlations in the medulla in sudden unexpected death in epilepsy (SUDEP): A postmortem study. Neuropathol Appl Neurobiol. 2021;47:157–170. doi:10.1111/nan.12638.
14. Leitner DF, Mills JD, Pires G, et al. Proteomics and transcriptomics of the hippocampus and Cortex in SUDEP and high-risk SUDEP patients. Neurology. 2021;96:e2639–e2652. doi:10.1212/WNL.0000000000011999.
15. Leitner DF, Faustin A, Verducci C, et al. Neuropathology in the north American sudden unexpected death in epilepsy registry. Brain Commun. 2021;3(3):fcab192. doi:10.1093/braincomms/fcab192.
16. Patodia S, Somani A, Thom M. Review: Neuropathology findings in autonomic brain regions in SUDEP and future research directions. Auton Neurosci. 2021;235:102862. doi:10.1016/j.autneu.2021.102862.
17. Schwarzacher SW, Rub U, Deller T. Neuroanatomical characteristics of the human pre-Bötzinger complex and its involvement in neurodegenerative brainstem diseases. Brain. 2011;134(Pt 1):24–35. doi:10.1093/brain/awq327.
18. Paxinos G, Xu-Feng H, Sengul G, Watson C. Chapter 8—organization of brainstem nuclei. In: Mai JK and Paxinos G, eds. The Human Nervous System. 3rd ed. Academic Press; 2012:260–327.
19. Yang CF, Feldman JL. Efferent projections of excitatory and inhibitory pre-Bötzinger Complex neurons. J Comp Neurol. 2018;526(8):1389–1402. doi:10.1002/cne.24415.
20. Yang CF, Kim EJ, Callaway EM, Feldman JL. Monosynaptic projections to excitatory and inhibitory pre-Bötzinger Complex neurons. Front Neurol. 2020;14:58. doi:10.3389/fnana.2020.00058.
21. Kinney HC, Richerson GB, Dymecki SM, Darnall RA, Nattie EE. The brainstem and serotonin in the sudden infant death syndrome. *Annu Rev Pathol.* 2009;4:517–530. doi:10.1146/annurev.pathol.4.110807.092322.

22. Kinney HC, Haynes RL. The serotonin brainstem hypothesis for the sudden infant death syndrome. *J Neuropath Exp Neurol.* 2019;78(9):765–779. doi:10.1002/jn.32062.

23. Zhang H, Zhao H, Zeng C, et al. Optogenetic activation of 5-HT neurons in the dorsal raphe suppresses seize-induced respiratory arrest and produces anticonvulsant effect in the DBA/1 mouse SUDP model. *Neurobiol Dis.* 2018;110:47–58. doi:10.1016/j.nbd.2018.01.003.

24. Petrucci AN, Joyal KG, Chou JW, Li R, Vencer KM, Buchanan GF. Post-ictal generalized EEG suppression is reduced by enhancing dorsal raphe serotonin neurotransmission. *Neuroscience.* 2021;453:206–221. doi:10.1016/j.neuroscience.2020.11.029.

25. Hornung J-P. Chapter 11—raphe nuclei. In: Mai JK and Paxinos G, eds. *The Human Nervous System.* 3rd ed. Academic Press; 2012:401–424.

26. Smith HR, Leibold NK, Rappoport DA, et al. Dorsal raphe serotonin neurons mediate CO2-induced arousal from sleep. *J Neurosci.* 2018;38(8):1915–1925. doi:10.1523/JNEUROSCI.2182-17.2018.

27. Kaur S, De Luca R, Khanday MA, et al. Role of serotoninergic dorsal raphe neurons in hypercapnia-induced arousals. *Nat Commun.* 2020;11(1):2769. doi:10.1038/s41467-020-16518-9.

28. Zhang H, Zhao H, Zeng C, et al. Optogenetic activation of 5-HT neurons in the dorsal raphe suppresses seizure-induced respiratory arrest and produces anticonvulsant effect in the DBA/1 mouse SUDP model. *Neurobiol Dis.* 2018;110:47–58. doi:10.1016/j.nbd.2018.01.003.

29. Mendonça CF, Kuras M, Nogueira FCS, et al. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer’s disease. *Neurobiol Dis.* 2019;130:104509. doi:10.1016/j.nbd.2019.104509.

30. Johnston ESB, Dammer EB, Duong DM, et al. Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. *Mol Neurodegener.* 2018;13(1):52. doi:10.1186/s13224-018-0282-4.

31. Xu J, Patassini S, Rustogi N, et al. Regional protein expression in human Alzheimer’s brain correlates with disease severity. *Commun Biol.* 2019;2:43. doi:10.1038/s42003-018-0254-9.

32. Drummond E, Nayak S, Faustin A, et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. *Acta Neuropathol.* 2017;133(6):933–954. doi:10.1007/s00401-017-1691-0.

33. Pires G, Leitner D, Drummond E, et al. Proteomic differences in the hippocampus and cortex of epilepsy brain tissue. *Brain Communications.* 2021;3(2):fcab021.doi:10.1093/braincomms/fcab021.

34. Drummond E, Nayak S, Pires G, Ueberheide B, Wisniewski T. Isolation of amyloid plaques and neurofibrillary tangles from archived Alzheimer’s disease tissue using Laser-capture microdissection for downstream proteomics. *Methods Mol Biol.* 2018;1723:319–334. doi:10.1007/978-1-4939-7558-7_18.

35. Doellinger J, Schneider A, Hoeller M, Lasch P. Sample preparation by easy extraction and digestion (SPEED)—A universal, rapid, and detergent-free protocol for proteomics based on acid extraction. *Mol Cell Proteomics.* 2020;19(12):209–222. doi:10.1074/mcp.TIR119.001616.

36. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics.* 2014;13(9):2513–2526. doi:10.1074/mcp.M113.031591.

37. Tyanova S, Temu T, Sintcyn P, et al. The perseus computational platform for comprehensive analysis of (proteo)omics data. *Nat Methods.* 2016;13(9):731–740. doi:10.1038/nmeth.3901.

38. Heberle H, Meireles GV, da Silva FR, Telles GP, Mingham R. Interactivenn: A web-based tool for the analysis of sets through venn diagrams. *BMC Biol.* 2015;15:169. doi:10.1186/s12859-015-0611-3.

39. Lake BB, Chen S, Sos BC, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat Biotecnol.* 2018;36(1):70–80. doi:10.1038/nbt.4038.

40. McDonald T, Puchowicz M, Borges K. Impairments in oxidative glucose metabolism in epilepsy and metabolic treatments thereof. *Front Cell Neurosci.* 2018;12:274. doi:10.3389/fncel.2018.00274.

41. Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. *J Neurosci Res.* 2017;95(11):2217–2235. doi:10.1002/jnr.24064.

42. Kumar A, Alhouri H, Abdellkader A, Shah AK, Juhasz C, Basha MM. Frontal lobe hypometabolism associated with sudden unexpected death in epilepsy (SUDEP) risk: An objective PET study. *Epilepsy Behav.* 2022;121:108185. doi:10.1016/j.yebeh.2021.108185.

43. Dietmier JW, Theparambil SM, Ruminiot I, Noor SI, Becker HM. Energy dynamics in the brain: Contributions of astrocytes to metabolism and pH homeostasis. *Front Neurosci.* 2019;13:1301. doi:10.3389/fnins.2019.01301.

44. Schönfeld P, Reiser G. Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. *J Cereb Blood Flow Metab.* 2013;33(10):1493–1499. doi:10.1038/jcbfm.2013.128.

45. Thom M, Michalak Z, Wright G, et al. Audit of practice in sudden unexpected death in epilepsy (SUDEP) post mortems and neuropathological findings. *Neuropathol Appl Neurobiol.* 2016;42(5):463–476. doi:10.1111/nan.12265.

46. Thom M, Boldrini M, Bundock E, Sheppard MN, Devinsky O. Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking. *Neuropathol Appl Neurobiol.* 2018;4(4):32–55. doi:10.1111/nan.12453.

47. Leitner DF, Connor JR. Functional roles of transferrin in the brain. *Biochim Biophys Acta.* 2021;1884(4):32–55. doi:10.1111/jb.2021.10.016.

48. Yip J, Geng X, Shen J, Ding Y. Cerebral glucoseoneogenesis and diseases. *Front Pharmacol.* 2016;7:521. doi:10.3389/fphar.2016.00521.

49. Thom M, Boldrini M, Bundock E, Sheppard MN, Devinsky O. Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking. *Neuropathol Appl Neurobiol.* 2018;4(4):32–55. doi:10.1111/nan.12453.

50. Leitner DF, Connor JR. Functional roles of transferrin in the brain. *Biochim Biophys Acta.* 2021;1884(4):32–55. doi:10.1111/jb.2021.10.016.

51. Dayon I, Cominetti O, Wojcik J, et al. Proteomes of paired human cerebrospinal fluid and plasma: Relation to blood-brain barrier permeability in older adults. *J Proteome Res.* 2019;18(3):1162–1174. doi:10.1021/acs.jproteome.9b00809.

52. Lindblad C, Pin E, Just D, et al. Fluid proteomics of CSF and serum reveal important neuroinflammatory proteins in blood-brain barrier disruption and outcome prediction following severe traumatic brain injury: A prospective, observational study. *Crit Care.* 2021;25(1):1–103. doi:10.1186/s13054-021-03503-x.

53. Seyfried NT, Dammer EB, Swarup V, et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer’s disease. *Cell Syst.* 2017;4(1):60–72.e4. doi:10.1016/j.cels.2016.11.006.